Clinical trials: CHD - Coronary Heart Disease
Dyslipidemia, Coronary Heart Disease
Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.
The primary purpose of this study is to test the safety and the effects of using an investigational drug regimen; once daily ABT-335 (Investigational drug) administered in combination with once daily atorvastatin calcium…
- Conditions
- Dyslipidemia, Coronary Heart Disease, Mixed Dyslipidemia
- Trial name
- NCT00300430
- Testing
- ABT-335 and rosuvastatin calcium, ABT-335 and atorvastatin calcium, ABT-335 and simvastatin
- Where
- United States
- Volunteers
- 1,911 people
- Sponsor
- Abbott
Coronary Arterioscleroses
EucaLimus Post-Market Registry
To collect post marketing surveillance data on consecutive patients with coronary heart disease intended to be or treated by the Eucalimus sirolimus eluting PTCA stent when used according to the Instructions for Use.
- Trial name
- NCT06621524
- Testing
- EucaLimus coronary stent system
- Where
- 10 sites in Czechia, Malaysia and 1 more
- Volunteers
- 251 people
- Sponsor
- OrbusNeich
Arrhythmia, Cardiovascular Diseases
Diagnostic Investigation of Sudden Cardiac Event Risk
The overall objective of the DISCERN study is to develop and validate a genomic diagnostic assay to identify patients at increased risk for lethal ventricular arrhythmias and sudden cardiac death (SCD).
- Conditions
- Arrhythmia, Cardiovascular Diseases, Heart Failure, CVD
- Trial name
- DISCERN (NCT00500708)
- Where
- 8 sites in United States
- Volunteers
- 1,564 people
- Sponsor
- CardioDx
Atherosclerosis
SB-480848 In Subjects With Coronary Heart Disease
This trial of SB-480848 in approximately 920 subjects with Coronary Heart Disease (CHD) or CHD-risk equivalent will examine whether SB-480848 produces sustained inhibition of plasma Lp-PLA2 activity, explore the effects of…
- Trial name
- NCT00269048
- Testing
- SB-480848
- Where
- 119 sites in United States, Argentina and 14 more
- Volunteers
- 969 people
- Sponsor
- GlaxoSmithKline
Hypercholesterolemia, Atherosclerosis
Ezetimibe Plus Atorvastatin Versus Atorvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03406)
To compare the efficacy of ezetimibe 10 mg added daily to ongoing treatment with atorvastatin 10 mg daily versus ezetimibe placebo added daily to ongoing treatment with atorvastatin 10 mg daily in reducing the concentration of…
- Trial name
- NCT00651404
- Testing
- Ezetimibe
- Volunteers
- 137 people
- Sponsor
- Organon and Co
Coronary Heart Disease, Multi Vessel Coronary Artery Disease
Optilene® Suture for Coronary Artery Bypass Graft Surgery
The study is a voluntary study, initiated by B. Braun to collect clinical data for Optilene® suture concerning its key indication.
- Trial name
- OPTICABG (NCT02546557)
- Testing
- Coronary Artery Bypass Graft surgery
- Where
- 4 sites in Germany, Italy and 2 more
- Volunteers
- 245 people
- Sponsor
- Aesculap AG
Coronary Heart Disease
A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381
This 2 arm study will assess the long term safety and efficacy of RO4607381 in patients with coronary heart disease or a coronary heart disease (CHD) risk equivalent who have completed study NC19453.
- Trial name
- NCT00400439
- Testing
- dalcetrapib (RO4607381)
- Where
- 9 sites in United States
- Volunteers
- 77 people
- Sponsor
- Hoffmann-La Roche
Coronary Heart Disease
PROTEUS: Evaluating the Use of Artificial Intelligence to Support Stress Echocardiography Testing for Heart Disease
PROTEUS is a multicentre, two arm, randomised controlled trial of a medical device to assess the impact of the introduction of EchoGo into the standard care pathway for stress echocardiology.
- Trial name
- PROTEUS (NCT05028179)
- Testing
- EchoGo
- Where
- 20 sites in United Kingdom
- Volunteers
- 2,338 people
- Sponsor
- Ultromics Ltd
Congenital Heart Disease, Congenital Heart Disease (CHD)
Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE Study
Starlight Cardiovascular, Inc. is sponsoring a prospective, multi-center, study to evaluate safety and effectiveness of the Lifeline Ductus Arteriosus Stent System.
- Trial name
- NCT07114718
- Testing
- Ductus Arteriosus Stent
- Where
- 11 sites in United States
- Volunteers
- 45 people
- Sponsor
- Starlight Cardiovascular Inc
Coronary Heart Disease
Assessment of the Lipid Lowering Effect of Rosuvastatin Compared to Atorvastatin in Subjects With Coronary Heart Disease
The purpose of this study is to compare the efficacy between two lipid lowering treatments, rosuvastatin (10-40 mg) and atorvastatin (20-80 mg) in reducing low-density lipoprotein cholesterol (LDL-C) levels after 16 weeks of…
- Trial name
- NCT00235950
- Testing
- Rosuvastatin or atorvastatin or simvastatin and clopidogrel
- Where
- 18 sites in Sweden
- Volunteers
- 255 people
- Sponsor
- AstraZeneca
Cardiovascular Diseases, Coronary Artery Disease
Study On Liprimar (Atorvastatin) In Patients With Coronary Heart Disease (CHD) And High Risk Of Cardiovascular Complications
In which CHD patients with high risk of CV complications are different doses of LIPRIMAR used? For this purpose, data on hyperlipidemia will be elicited over and above the basic nosographic and demographic data, concomitant…
- Trial name
- LIGHT (NCT00993915)
- Testing
- Atorvastatin
- Volunteers
- 687 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypercholesterolemia, Dyslipidemia
Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin
The purpose of this study is to compare the efficacy and safety of pitavastatin with that of simvastatin in patients with risk factors for heart disease.
- Trial name
- NCT00309738
- Testing
- pitavastatin, simvastatin
- Where
- 35 sites in Denmark, Netherlands and 2 more
- Volunteers
- 355 people
- Sponsor
- Kowa Research Europe
Coronary Heart Disease
Inclisiran Effectiveness in China: a Pragmatic Randomized Trial
The current study will be conducted to evaluate the real-world effectiveness of inclisiran relative to standard of care (SoC) in Chinese patients with coronary heart disease (CHD), not only with the low-density lipoprotein…
- Trial name
- V-INVINCIBLE (NCT06941792)
- Testing
- inclisiran sodium injection, Standard of Care
- Where
- 19 sites in China
- Volunteers
- 1,590 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Heart Disease
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL180
The design of this study will enable an extensive evaluation of safety, tolerability, and PK-PD relationship following 4 weeks of dosing in patients with Coronary heart Disease
- Trial name
- NCT00907998
- Testing
- APL180
- Where
- 11 sites in United States, Denmark and 3 more
- Volunteers
- 104 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Heart Disease, Cardiac Dysfunction
Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
A randomized controlled trial was conducted to evaluate the efficacy and safety of Yangxinshi tablets in improving the condition of patients with coronary heart disease complicated by cardiac dysfunction.
- Trial name
- HEARTPOWER (NCT07110415)
- Testing
- Yangxinshi tablet, Blank control
- Where
- 96 sites in China
- Volunteers
- 2,708 people
- Sponsor
- SPH Qingdao Growful Pharmacetical Co.,Ltd
Coronary Heart Disease, Stable Angina Pectoris
BuMA OCT Study(A Comparative Evaluation of the Extent of Neointima Formation at 3 Months After Implantation Using OCT)
The objective of this study is a comparative evaluation of BuMA stent and of EXCEL stent in terms of the extent of neointima formation at 3 months after implantation using OCT.
- Conditions
- Coronary Heart Disease, Stable Angina Pectoris, Unstable Angina Pectoris, Silent Myocardial Ischemia
- Trial name
- NCT01752582
- Testing
- BuMA stent, EXCEL stent
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sino Medical Sciences Technology Inc.
Hypercholesterolemia, Coronary Heart Disease
Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET)
In this study the effect of the switch to rosuvastatin from another statin (fluvastatin, pravastatin, simvastatin, atorvastatin) was evaluated in high-risk patients with and without evident CHD and LDL-C ≥ 3.2 mmol/l.
- Trial name
- NCT00396110
- Volunteers
- 3,889 people
- Sponsor
- AstraZeneca
Nonfatal Myocardial Infarction, Coronary Death
Association Between Low Dose Acetylsalicylic Acid (ASA) and Proton Pump Inhibitors and Risk of Acute Myocardial Infarction or Coronary Death
The purpose of this study is to estimate the risk of myocardial infarction (MI)/coronary death associated with use of monotherapy low dose ASA (single antiplatelet) as well as concomitant use of monotherapy low dose ASA and…
- Trial name
- NCT01360047
- Where
- Spain
- Volunteers
- 39,513 people
- Sponsor
- AstraZeneca
Supraventricular Tachycardia (SVT), Congenital Heart Disease (CHD)
MAGiC - Congenital Heart DIsease
The goal of this observational study is to collect real world performance and to confirm the effectiveness and safety of the MAGiC Ablation Catheter for the treatment of supraventricular tachycardia in adult patients with…
- Trial name
- MAGiC-CHD (NCT07812818)
- Testing
- Cardiac ablation using the MAGiC Ablation Catheter
- Volunteers
- 40 people
- Sponsor
- Stereotaxis
Cardiovascular Disease, Cerebrovascular Accident
A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels
The primary objective of this study is to determine the degree of additional reduction in cardiovascular risk that was accrued to patients by lowering their LDL-C beyond the currently accepted minimum target level for patients…
- Conditions
- Cardiovascular Disease, Cerebrovascular Accident, Coronary Heart Disease
- Trial name
- TNT (NCT00327691)
- Testing
- Atorvastatin
- Where
- 314 sites in United States, Australia and 12 more
- Volunteers
- 8,600 people
- Sponsor
- Pfizer